Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
BIOTRICITY INC. (BTCY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 8-K Quarterly results
Docs: "Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates REDWOOD CITY, CA / ACCESSWIRE / August 15, 2023 / Biotricity Inc. , a Technology-as-a-Service company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023."
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/20/2023 8-K Quarterly results
07/05/2023 8-K Quarterly results
Docs: "Biotricity Reports Business Update, Financial Results for Q4 and Full Year FY23; Company Posts Robust Revenue Growth, Overall Higher Margins, with Lower SG&A Driving Clear Path to Positive Cash Flow",
"Biotricity Announces Reverse Stock Split REDWOOD CITY, CA / ACCESSWIRE / June 30, 2023 / Biotricity Holdings, Inc. , a medical diagnostic and consumer healthcare technology company, today it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023."
06/29/2023 10-K Annual Report for the period ended March 31, 2023
05/18/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "SUBSCRIPTION AGREEMENT",
"CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIOTRICITY INC. CONVERTIBLE PROMISSORY NOTE",
"WARRANT THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED , OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. No. [__] Issue Date: [DATE] Biotricity Inc. Common Stock Purchase Warrant _________________ THIS CERTIFIES THAT, for value received, [_____] is entitled to subscribe for and purchas...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
04/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BIOTRICITY INC. 2023 INCENTIVE PLAN SECTION 1. PURPOSE The purpose of the Biotricity Inc. 2023 Incentive Plan is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its Related Companies by providing them the opportunity to acquire a proprietary interest in the Company and to align their interests and efforts to the long-term interests of the Company’ s stockholders. SECTION 2. DEFINITIONS Certain capitalized terms used in the Plan have the meanings set forth in Appendix A. SECTION 3. ADMINISTRATION 3.1 Administration of the Plan The Plan shall be administered by the Board or the Compensation Committee, which shall be composed of two or more directors. The members of the Compensation Committee shall me...",
"APPROVAL OF THE BIOTRICITY, INC. EMPLOYEE STOCK PURCHASE PLAN OVERVIEW"
03/22/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/15/2023 4 Rosa David A (Director) has filed a Form 4 on BIOTRICITY INC.
Txns: Granted 75,930 options to buy @ $1.94, valued at $147.3k
03/14/2023 4 Al-Siddiq Waqaas (President, CEO and Chairman) has filed a Form 4 on BIOTRICITY INC.
Txns: Granted 350,000 options to buy @ $1.25, valued at $437.5k
Granted 350,000 options to buy @ $1.75, valued at $612.5k
Granted 1,000,000 options to buy @ $0.81, valued at $810k
03/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 4 Ayanoglou John (CFO) has filed a Form 4 on BIOTRICITY INC.
Txns: Granted 50,000 warrants @ $0.73, valued at $36.5k
Granted 50,000 warrants @ $0.73, valued at $36.5k
Granted 50,000 warrants @ $0.73, valued at $36.5k
Granted 50,000 warrants @ $0.73, valued at $36.5k
Granted 50,000 warrants @ $0.48, valued at $24k
Granted 50,000 warrants @ $0.91, valued at $45.5k
Granted 50,000 warrants @ $0.66, valued at $33k
Granted 50,000 warrants @ $0.58, valued at $29k
Granted 50,000 warrants @ $0.63, valued at $31.5k
Granted 50,000 warrants @ $0.974, valued at $48.7k
Granted 50,000 warrants @ $1.367, valued at $68.4k
03/02/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/14/2023 10-Q Quarterly Report for the period ended December 31, 2022
01/27/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/18/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biotricity Reports Financial Results for Fiscal 2023 Second Quarter"
09/09/2022 4 Rosa David A (Director) has filed a Form 4 on BIOTRICITY INC.
Txns: Granted 31,106 options to buy @ $2.4, valued at $74.7k
09/01/2022 3 White Chester P (Director) has filed a Form 3 on BIOTRICITY INC.
08/16/2022 8-K Quarterly results
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
07/14/2022 10-K Annual Report for the period ended March 31, 2022
06/29/2022 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
05/16/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
05/06/2022 8-K Quarterly results
04/27/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/26/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/14/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
04/08/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
03/22/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/22/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "275 Shoreline Drive, Suite 150 Redwood City, California 94065",
"AT THE MARKET OFFERING AGREEMENT March 22, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy